Asian Currencies Hold Steady as Fed Outlook Offsets Middle East Tensions 
Lockheed Martin Unveils Lower-Cost Patriot ACE Interceptor to Meet Rising Air Defense Demand 
China Holds Loan Prime Rates Steady for 14th Month as Economic Recovery Remains Uneven 
ASML Trillion-Dollar Valuation: Can Europe’s AI Chip Giant Reach the Historic Milestone? 
Japan Core Inflation Seen Rising in June, Strengthening BOJ Rate Hike Outlook 
KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
Trump Set to Unveil New Tariffs on Dozens of Countries as Global 10% Duty Nears Expiration 
Germany Producer Prices Rise 1.8% in June, Missing Forecasts 
TSMC Sees Multi-Year AI Chip Demand as Arizona Expansion Reaches $265 Billion 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
Gold Climbs Above $4,000 as Middle East Tensions and Fed Outlook Drive Safe-Haven Demand 
Seven & i Eyes Żabka Stake in Major European Expansion Push 
US Stock Futures Rise as AI Optimism Lifts Tech, 3M Jumps on Strong Earnings 
SpaceX Eyes Pentagon AI Deal as Cloud Pricing Strategy Pressures CoreWeave 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
Chalco Shares Jump as Chinalco Plans Up to $300 Million Stake Increase 
Brent Oil Jumps 16% for Best Week Since April as US-Iran Conflict Fuels Supply Fears 
Celltrion Inc., a biopharmaceutical company headquartered in Incheon, South Korea, is merging with its Celltrion Healthcare subsidiary in an effort to strengthen its business synergy or combined effort. The biosimilar producer and its biosimilar marketing unit are set to be consolidated this year.
Seo Jung Jin, Celltrion Group’s chairman, said on Thursday, Aug. 17, that once Celltrion is incorporated with Celltrion Healthcare, the newly-formed entity will also take in Celltrion Pharma. The chairman said this integration will eventually happen later but did not provide an exact time frame. After all the mergings, Celltrion, Celltrion Healthcare, and the company’s chemical pharma producer will work together as one.
According to The Korea Times, Celltrion revealed its plan to acquire Celltrion Healthcare during the company’s recent regulatory filing. The changes will also entail the issuance of new shares of Celltrion to shareholders of Celltrion Healthcare, and the merger ratio is expected to stand at 1:0.4492620.
It was mentioned that the Celltrion chairman holds a 95% stake in Celltrion Holdings which in turn holds a 20.02% stake in Celltrion. The holdings also have a 35.54% stake in Celltrion Healthcare and a 54.96% stake in Celltrion Pharm.
"Celltrion is expected to complete the merger of Celltrion Healthcare by the end of the year, followed by the next merger with Celltrion Pharm in the next six months," Seo Jung Jin shared during an online conference.
The Celltrion Group said it will merge the mentioned companies, but the plan still needs the approval of shareholders. This may be completed on October 23 at the shareholders' meeting. Celltrion and Celltrion Healthcare will eventually be dissolved after the merger.
To date, while the merger is still being processed, The Korea Herald reported that Celltrion is focusing on producing and developing bio-pharmaceutical products while Celltrion Healthcare is working more on selling these products.
Photo by: Celltrion Press Room
